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Abstract 
 
Antinuclear antibodies are autoantibodies that target intracellular antigens, 
abnormal level of antinuclear antibodies are found in patients with Systemic Autoimmune 
Rheumatic Diseases (SARD); are classified into a class of non-organ specific 
autoimmunity, as a different of autoantibodies attack multiple organ systems. It includes 
six different types of diseases: Systemic Lupus Erythematosus (SLE), Sjogren Syndrome 
(SjS), Systemic Sclerosis (SSc), Polymyositis (PM), Dermatomyositis (DM) and 
Rheumatoid arthritis (RA). The antinuclear antibodies can be detected using serological 
tests, the antinuclear antibodies test; termed as ANA. Thus, it is considered as a primary 
test for diagnosing patients with SARD. This test can be done using different techniques, 
the two most common techniques are: Indirect Immunofluorescence Assay (IIF) and 
Enzyme Linked Immunosorbent Assay (ELISA). In addition, western blot can be used to 
characterize the anti-nuclear autoantibodies. The identification of anti-nuclear 
autoantibodies in patient serum is a key role in SARD diagnosis. Different purified antigens 
of cells from mice, calves or human carcinoma cells were used in ELISA and western blot, 
because the specificity of ANA test depends on the quality of antigens used. This study is 
mainly aimed at developing ANA screening test using continuous THP1 cell lines, non-
pathogenic Leishmania tarentolae and salmon sperm DNA, because they are suitable in 
ELISA testing, due to the large nuclei of THP1 cells, and the high rich of DNA of the 
kinetoplast in Leishmania tarentolae.  The results gave 100% positivity using THP1, 
Leishmania tarentolae and salmon sperm DNA in ELISA assay. The autoantibodies 
against dsDNA gave a better result in salmon sperm DNA ELISA than leishmanial and 
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THP1 extract. However, for the other anti-nuclear autoantibodies, the results of THP1 and 
Leishmanial extract ELISA were better than salmon sperm DNA ELISA. Furthermore, the 
results were better in THP1 nuclear extract compared to leishmanial extract. In addition, 
results showed that different anti-nuclear autoantibodies can be identified using the 
immunoblotting of THP1 and leishmanial separated proteins, but the more relevant reactive 
bands appeared in THP1 nuclear extracts. 
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Introduction 
 
1.1 Immune tolerance 
 
Our bodies are armed with strong immune system that aims to fight and eliminate foreign 
bodies. In addition, our immune system has the ability to distinguish between self and non-self-
antigens. Thus, it only responses to foreign antigens, this is known as immune tolerance.  
Our immune system builds this tolerance by process of both central-tolerance and 
peripheral tolerance (Kyewski & Klein, 2006). In central tolerance, our immune cells; 
lymphocytes, learn to discriminate between self and non-self during their development, T cells in 
the thymus and B cells in bone marrow. In thymus, T cells become mature after proliferation, 
differentiation and selection (Kyewski & Klein, 2006). During early thymocyte development, T 
cell precursors move from bone marrow to thymus (Schwarz & Bhandoola, 2006), and become 
double negative cells; these cells neither express CD4 nor CD8 receptors on their surfaces. Then, 
these cells pass through four stages in order to rearrange their T-cell receptor gene loci. Cells 
with rearranged T cell receptor (TCR) beta chain are able to proliferate and initiate 
rearrangement of their TCR Alpha chains, and become double positive cells. This means, the 
cells have both CD4 and CD8 receptors. Later, they undergo negative and positive selection in 
thymic cortex (Kyewski & Klein, 2006; Sprent & Kishimoto, 2001). 
The double positive cells are exposed to the Major Histocompatibility Complex (MHC) 
molecules; MHCI and MHCII, in thymic epithelial cells.  The double positive cells that don’t 
respond, or that bind with a high affinity to MHC molecules are deleted by negative selection. 
This means, only double positive cells that bind intermediately to MHC molecules are positively 
selected and survived. After that, they are presented to self-antigen with MHC molecules in 
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medulla. This process called, negative selection. Cells that don’t respond to self-antigen become 
mature lymphocytes expressing either CD4 or CD8. However, auto reactive cells that respond to 
self-antigen are marked for death and removed (Judith A. Owen, 2013; Kyewski & Klein, 2006; 
Sprent & Kishimoto, 2001).  
A few of autoreactive mature T cells can escape to peripheral immune system. By 
different mechanisms of peripheral tolerance; either by clonal anergy or deletion, these cells are 
regulated and suppressed by regulatory T cells (Judith A. Owen, 2013; Xing & Hogquist, 2012). 
The anergy mechanism lead to inactivate the response of auto reactive T cells toward self-
antigens, and this happen by blocking of signals induced from CD28 ligation. This state is 
known as T cell hyporesponsiveness. The other way is by deletion of the autoreavitve cells, these 
cells are died through Fas- mediated apoptosis (Xing & Hogquist, 2012).  
The B cell tolerance occurs in bone marrow where B cell precursors undergo steps to 
become mature B cells. At first, B cell precursors become pre-B cells expressing receptors on 
their surface. The fate of any B cells that fail to express receptors is death. These pre-B cells that 
can recognize wide varieties of protein, such as self- antigens are either marked for death or 
locked away. However, some cells are subjected for receptor editing. Then, they leave bone 
marrow to enter peripheral system where peripheral B cell tolerance are built. When these naïve 
B cells become activated and bind to antigens with moderate affinity, they proliferate, and then 
transform to class switching, somatic hyper mutation or plasma cells. While those cells that bind 
to antigens with high affinity are killed and removed (Goodnow, Adelstein, & Basten, 1990; 
Judith A. Owen, 2013).  
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1.2 Autoimmune disease 
The autoimmunity is defined as a disease caused by an unexpected response of immune 
system against self-components, resulting in severe injury in tissues and organs (Ghazvini, 
2010). Thus, it is considered as a chronic disease, and it may cause significant mortality and 
morbidity (Ghazvini, 2010; Walsh & Rau, 2000). This disease affects about 5%-7% of the 
population worldwide, 78% of them are women(Smith & Germolec, 1999). The prevalence of 
this disease is rapidly increasing in the developing countries. In the United States, it mostly 
affects up to 23 million Americans(Walsh & Rau, 2000). In addition, depending on several 
studies in low and middle income countries; South Africa, Iran and Philippine, the autoimmune 
diseases; such as SLE, affects more than 100 million people (Vento & Cainelli, 2016).    
There are 80 different types of auto immune disease. Scientists found it difficult to 
classify autoimmune diseases into groups, as their causative mechanisms are still not fully 
understood. However, these diseases are traditionally categorized into two groups:  organ-
specific and systemic autoimmune disease. Organ specific autoimmunity is directed against one 
specific organ, while in systemic autoimmunity, the immune response is directed against many 
different organs which is not restricted to one organ (Judith A. Owen, 2013)  
The autoimmune diseases are mostly happened when peripheral tolerance is dysregulated 
in individuals with autoimmune disease prone genotype. In other words, the immune tolerance 
may collapsed in individuals who are genetically susceptible to autoimmune diseases (Mackay, 
2000). Thus, in presence of any triggers such as: environment, sex hormones, neuroendocrine 
influence or autoantigen, the controlled auto-reactive cells become activated after responding to 
them. This leads to serious damage to cells and organs achieved by the mechanism of humoral or 
cell- mediated responses (Smith & Germolec, 1999). In addition, autoimmune disease may also 
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developed when individual is infected by viral or bacterial disease. In this case, as viral and 
bacterial agents mimic host tissues, the immune system starts recognizing self-tissues and 
attacking them (Wucherpfennig & Strominger, 1995). Rheumatic fever is a good example for 
this type of autoimmune disease where occurs after streptococcal infection. These bacterial 
antigens are mimic the heart muscle. Therefore, the antibodies will response against both 
streptococcal antigens and heart muscle ( Denick, 1992). 
Furthermore, there are sex differences in autoimmune disease development. Women are 
susceptible to the autoimmune disease three times more than men (Beeson, 1994).  In women, 
the immune system responses to infection and vaccination is highly activated than men, as it 
produces more antibodies and T helper 2 cells. Hence, the high level of antibodies increase the 
risk of developing an autoimmune disease. In addition, the ovarian hormone, estrogen is also 
known to have the ability to alter the immune response, and result in developing autoimmune 
disease (Cutolo, Sulli, Seriolo, Accardo, & Masi, 1995; Cutolo, Sulli, & Straub, 2012). 
1.3 The systemic autoimmune rheumatic diseases (SARD) 
This group includes: Systemic Lupus Erythematosus (SLE), Sjogren Syndrome (SjS), 
Systemic   Sclerosis (SSc), Polymyositis (PM), Dermatomyositis (DM) and Rheumatoid arthritis 
(RA)(Judith A. Owen, 2013). As previously mentioned, the immune response attack different 
organs and tissues in these diseases, and the tissue damage caused by auto-antibodies or by 
accumulation of immune complexes. The diagnosis of systemic autoimmune rheumatic diseases 
depends on both clinical manifestation and laboratory tests. The most relative serological test for 
SARD is ANA test (Mahler, Pierangeli, Meroni, & Fritzler, 2014; Pisetsky, 2012). 
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1.3.1. The Antinuclear antibodies (ANA)  
The antinuclear antibodies are immunoglobulins that encounter against the nuclear and 
cytoplasmic components (Cabiedes & Nunez-Alvarez, 2010).  The presence of ANA in the 
circulation is not always associated to the autoimmune disease. It is known that the ANA may be 
present in healthy individuals, but in a low titer. Further, Individuals may show a high titer of 
ANA in response to infectious disease. However, they are reduced whenever the infectious is 
resolved (Tan et al., 1997).  
 In autoimmune diseases, such as systemic autoimmune rheumatic diseases, high levels of 
autoantibodies are produced to attack nuclear parts inside cells. These antinuclear antibodies 
include two groups based on their detection in circulation: Autoantibodies against DNA and 
histone: They are against both single and double stranded DNA, and histones. These 
autoantibodies are found with a high level in Systemic Lupus Erythematosus (SLE) patients. The 
other group is autoantibodies against extractable nuclear antigens (ENA) (Cabiedes & Nunez-
Alvarez, 2010; Kumar, Bhatia, & Minz, 2009; Mahler, Meroni, Bossuyt, & Fritzler, 2014; 
Mahler, Pierangeli, et al., 2014; Muro, 2005): Those are extractable antigens from nuclei, 
including:  
A) Anti- smith (sm) antibodies: The autoantibodies against smith antigen were first 
described by Tan and Kunkel, in 1966 (Tan & Kunkel, 1966). These 
autoantibodies are very specific to SLE disease. Their presence with other 
autoantibodies against dsDNA, nucleosomes and riposomal P-Proteins considered 
as pathognomonic for the disease (Gill, Quisel, Rocca, & Walters, 2003). 
Anyway, they are only found in 20% of SLE patients (Wenzel, Bauer, Bieber, & 
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Bohm, 2000). The smith antigens are a small nuclear ribonucleoproteins 
(snRNPs) present in snRNPs core unit. It composed of nine polypeptides (B1, B’, 
B3, D1, D2, D3, E, F and G) responsible for splicing of pre-mRNA. Their 
molecular weight ranges from 9 to 29.5 kDa. Autoantibodies commonly presented 
against B and D polypeptides (Caponi, Bombardieri, & Migliorini, 1998). The 
smith antigens are mimic to proteins found in Epestein-Barr virus. So that, anti-
Sm antibodies are directed against smith antigens as result of Epestein-Barr virus 
infection (Sundar et al., 2004; Zieve & Khusial, 2003).  
B) Anti-nuclear ribonucleoproteins (nRNP): The antigen of these auto-antibodies are 
presented in the core unit of snRNPs, U1-nRNP. It contains specific proteins 70K, 
A and C (Benito-Garcia, Schur, Lahita, & American College of Rheumatology Ad 
Hoc Committee on Immunologic Testing, 2004). These auto-antibodies can be 
directed against nRNPs either by the molecular mimicary to Epestein-Barr virus 
or by nuclear component presentation (Venables, 2006).They are also found in 
SLE patients with ratio of 30-40% (Tan & Kunkel, 1966). They are detected in 
SSc and PM/DM diseases as well (Houtman et al., 1985; Houtman et al., 1986).  
 
Anti-SSA/Ro and anti-SSB/La antibodies: They are detected in 30-60% of 
Sjogren syndrome (Hernandez-Molina, Leal-Alegre, & Michel-Peregrina, 2011; 
Manoissakls, 2001; Peene, Meheus, Veys, & De Keyser, 2002), and also in 20%-
60% of SLE disease (Wenzel et al., 2000; Zieve & Khusial, 2003). The SSA/Ro 
antigens are ribonucleoprotein consists of RNA molecule and protein with 
molecular weight of 60 kDa. The SSA/Ro antigen contribute in activating mRNA. 
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The 60 kDa protein is commonly targeted by anti-SSA/Ro. The antigen of 
SSB/La is a 48 kDa phosphoprotein. This protein is considered as a helper for 
enzyme of RNA polymerase III. The anti-SSB/La antibodies are frequently found 
in parallel with Anti-SSA (Ben-Chetrit, 1993; Hernandez-Molina et al., 2011; 
Peene et al., 2002).  
C) Anti Scl-70 antibodies: The antigen of this autoantibody is topoisomerase I. It is 
located inside the nucleolus (Guldner et al., 1986). Further, this enzyme 
participate in DNA replication and transcription. Its molecular weight 110 kDa. 
(Guldner et al., 1986). However, in western blot, it was found to have a molecular 
weight of 70 kDa.(Aeschlimann et al., 1989) The anti Scl-70 antibodies are highly 
associated with Systemic sclerosis patients (Douvas, Achten, & Tan, 1979).  
D) Anti- Jo-1 antibodies: They are specific maker for polymyositis with ratio of 20-
30%. They are less frequently found in dermatomyositis diseases. Anti- Jo-1 
antibodies target hisyidyl tRNA sythetase. This enzyme catalyzes tRNA and 
histidine binding during protein synthesis. The molecular weight of this enzyme is 
50 kDa (Mescam-Mancini et al., 2015; Schmidt et al., 2000; Shinjo & Levy-Neto, 
2010; Sugie, Tonomura, & Ueno, 2012).  
1.3.2. Rheumatoid arthritis (RA) 
It is a common chronic inflammatory disease occurs when the auto-reactive T cells attack 
tissue in joints, result in joint swelling, joint tenderness, and destruction of synovial joints. It may 
be also attacks bones, cartilages, skin, lungs and kidneys. The chronic case of disease may leads 
to severe disability and premature mortality (Schumacher, Pessler, & Chen, 2003) . The RA 
affects individuals during middle age. Further, it affects women two and half times more than 
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men. In this disease, many auto antibodies are produced, the most common known as rheumatoid 
factors, class of IgM. They can bind to fragment of Fc region of IgG, forming IgM-IgG 
complexes which deposit into joints. The deposition of IgG-IgM complex into joints leads to 
complement cascade activation. It also leads to develop hypersensitive reaction type III which 
resulting in joint inflammation (Aletaha et al., 2010a). 
RA are diagnosed by symptom of patient, and by other tests; such as imaging and 
serological tests. The X-ray for hands and foots support the diagnosis of RA, as it shows the 
affected joints. Usually, the specific serology test used for diagnosing RA are Rheumatoid factor 
(RF) antibody and Anti-Citrullinated Protein Antibody (ACPA). Though patients with RA also 
show a high level of ANA, they overlap with other autoimmune diseases. Thus, ANA test is not 
usually done as the test is not specific for RA (Agmon-Levin et al., 2014; Aletaha et al., 2010b; 
Bas et al., 2002; Schumacher et al., 2003) 
1.3.3. Systemic Lupus Erythematosus (SLE)  
It is a chronic disease caused by producing of different auto antibodies to a variety of 
self-antigens. It affects many organs including: skin, joints, kidney, lung, heart, and 
gastrointestinal tract. There are different and mixed clinical manifestations, depending on the 
auto antibodies presented in the affected individual. The initial clinical manifestations of disease 
are: Malar rash, fever, weakness, hair loss, musculoskeletal symptoms, vascular abnormalities, 
and photosensitivity. In the severe case, other manifestations may include: hemolytic anemia, 
renal failure, arthritis, inflammatory serositis, lymphopenia, thrombocytopenia, and neurological 
problems(Judith A. Owen, 2013). In SLE disease, the autoantibodies to dsDNA and small 
nuclear ribonucleoproteins (snRNPS); such as smith antigen (Sm), are mostly produced. 
Anyway, the level of anti-Sm antibodies are constant. Thus, they are not associated with disease 
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activity. In addition, other different autoantibodies are also produced but in a variable level, such 
as, autoantibodies to histone proteins, RNA binding proteins, and DNA polymerase components. 
These autoantibodies form immune complexes which resulting in complement activation. It also 
develop type III hypersensitive reaction causing nephritis, skin lesions and arthritis (Gill et al., 
2003; Smith & Germolec, 1999; Tan & Kunkel, 1966; Venables, 2006; Wenzel et al., 2000; 
Zieve & Khusial, 2003).  
The prevalence of SLE is different between genders, ages, races and geographic 
locations. It affects women ten times more than men, and it usually affects individual between 
ages of 45-64 (Danchenko, Satia, & Anthony, 2006). In racial tendencies studies, it showed that 
SLE frequently affects non-Caucasian individuals (Housey et al., 2015; Ward, 2004). For 
instance, it was reported that the prevalence rates in UK at the Nottingham area were 3.7 in 
100,000 men and 45.4 in 100,000 women. In addition, he found that the prevalence is more 
amongst Afro-Caribbean groups (Hopkinson, Doherty, & Powell, 1993). 
The diagnosis of SLE is based on both clinical and laboratory criteria. The ANA test are 
done to detect the high level of antinuclear antibody to double-stranded DNA antigen (anti- 
dsDNA), and other autoantibodies with variable level such as anti-Sm, anti-SSA, anti-SSB and 
anti-nRNPs (Cabiedes & Nunez-Alvarez, 2010; Gill et al., 2003).  
1.3.4. Sjögren’s Syndrome (SjS): 
It is a chronic autoimmune inflammatory disease that affects exocrine glands; commonly 
lacrimal and salivary glands, leading to their functional impairment which results in 
keratoconjunctivits sicca and xerostomia. There are two type of Sjögren’s syndrome, Primary 
and Secondary. The most common type is Primary Sjögren’s syndrome which occurs 
independently. The prevalence of this disease around 1 to 3%.  It can affects all of ages and both 
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sexes, but it mostly affects women with ratio 9:1 of women to men. Secondary Sjögren’s 
syndrome occurs in people who have another rheumatologic disorder, most commonly 
rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) (Tincani et al., 2013; 
Voulgarelis & Tzioufas, 2010). Furthermore, patients with SjS have an increased incidence of 
lymphoma.  
The diagnosis of Sjögren’s syndrome is highly dependent on clinical manifestation and 
on autoimmune reactivity such as, the presence of lymphatic infilitrative lesions in the salivary 
gland. In addition, detection of auto antibodies against Ro(SSA) and La(SSB) in patient 
serum(Manoissakls, 2001). 
1.3.5. Systemic Sclerosis (SSc)  
It is a multisystem autoimmune disease of unknown etiology that involves the micro 
vascular system and connective tissue. It characterized by widespread vascular injury and 
progressive fibrosis of skin and internal organs which may lead to death (Casale, Buonocore, & 
Matucci-Cerinic, 1997). Skin thickening is the main symptom of SSc disease, and this due to the 
increase of collagen production. Other symptoms may include arthritis joint and internal organs. 
However, the symptoms of disease depend on the form of SSc disease; limited and diffuse 
cutaneous. In limited SSc disease, it affects face, hands and feet. But the diffuse cutaneous 
affects many regions of the skin, and internal organs and systems (Silman & Newman, 1996).  
 SSc disease is a rare disease, its onset is ranging from 30 to 55. It affects most of racial 
groups in all geographical areas. Anyway, some studies showed that black people at a high risk 
to develop the disease compared to White people. Furthermore, women from three to four times 
are more common to have the disease compared to men (Tager & Tikly, 1999).   
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The diagnosis of systemic sclerosis is based on combination of clinical and laboratory 
features. Patients with Systemic sclerosis present auto antibodies against a variety of nuclear and 
cytoplasmic antigens, the unique one is Anti-Scl-70 (Casale et al., 1997). 
   
1.3.6. Polymyositis (PM) and Dermatomyositis (DM)  
They are an idiopathic inflammatory myopathies with incidence of 1:100,100 per year. 
They predominantly affect skeletal muscles, resulting in muscle inflammation and weakness. 
Other organ systems may be involved such as: skin, cardiac, gastrointestinal, and pulmonary 
systems(Khan & Christopher-Stine, 2011). PM and DM may occur in isolation or in connection 
with connective tissue disease or cancer. The cause of disease is not fully understood until now. 
However, different factors may lead to cause the disease such as: genetic, Toxoplasma gondii or 
Coxasckie A virus infection, or stress. The autoantibodies detection help in disease diagnosis. 
The anti-Jo-1 antibodies are found in PM and DM disease with ratio of 70%. (Hak, de Paepe, de 
Bleecker, Tak, & de Visser, 2011) 
1.4 ANA detection techniques 
Different immunological techniques are previously used to detect ANA. The first method 
is used by Hargraves, in 1947, to detect Lupus Erythematosus (LE) cells in bone marrow in order 
to diagnose Systemic Lupus Erythematosus (SLE). He gave an evidence that LE cells react with 
proteins and DNA inside the nucleus. Therefore, this method called Lupus Erythematosus (LE) 
cell test (Hargraves, Richmond, & Morton, 1948). However, this test also showed a positive 
results in other autoimmune diseases. 
In 1959, Holman explained the phenomenon of LE cell. He showed that LE cells are a 
macrophages, inside their nuclei inclusion of degraded nuclear fractions (Holman & Deicher, 
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1959). After that, different techniques were developed. Most common techniques used are 
Indirect Immunofluorescent assay (IFA) and Enzyme Linked Immunosorbent Assay (ELISA). 
 
   
1.4.1. Indirect Immunofluorescene assay (IIF) 
In 1957, Friou applied the Indirect immunofluorescent assay for ANA detection (Friou, 
1958). At that time, it was the only gold standard technique used for SARD diagnosis due to its 
high sensitivity and specificity (Copple, Sawitzke, Wilson, Tebo, & Hill, 2011; Meroni & Schur, 
2010). This technique is performed by incubating the patient serum on slide coated with 
substrate. After that, a fluorescence tagged anti-immune globulin G antibodies are added to 
visualize the bounding antibodies to nucleus of substrate used by fluorescence 
microscope(Meroni & Schur, 2010).  
Different substrates were previously used, such as: HeLa cells, tissue sections and 
chicken erythrocytes. In 1966, Tan modified the IIF technique using a substrate of liver or 
kidneys of mice (Tan & Kunkel, 1966). In 1975, HEp-2 cells were introduced as a substrate in 
IIF, and they are most commonly used for ANA detection until now, as they increased the 
sensitivity of the technique. These are cultured cells originate from human laryngeal squamous 
cell carcinoma (Buchner, Bryant, Eslami, & Lakos, 2014). They have a large nuclei, high rate of 
mitosis, and on their surfaces hundred antigens are presented. This increase their ability in 
detection of different auto antibodies (Muro, 2005). 
The evaluating of cell staining results depend on a five major nuclear patterns: 
homogenous, speckled, centromere, nucleolar and nuclear.  These are most commonly 
recognized patterns detected on Hep-2 substrates (Buchner et al., 2014). The homogenous 
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pattern is characterized by condensed chromatin of the mitotic cells. This pattern is the result of 
anti-dsDNA antibodies. In speckled pattern, two patterns are seen, fine and coarse. Fine or 
diffuse nuclear staining are seen in fine speckled pattern, and it is associated with anti-SSA and 
anti SS-B. The coarse pattern shows granular nuclear staining, as result of anti-sm and anti-RNP. 
In centromere pattern, multiple nuclear dot are shown, caused by anti-CENP antibodies. The 
nucleolar pattern are associated with anti-RNA polymerase III, anti-fibrillarin and anti-Th/To. It 
is a homogenous or speckled staining of nucleoli. The pattern nuclear is shown as result of anti-
sp100. 
In 1976, substrate of crithidia was used in IFF to detect the anti-dsDNA in sera of SLE 
patients. This species has a kinetoplast which is contains a large amount of double stranded DNA 
(Slater, Cameron, & Lessof, 1976).   
1.4.2. The enzyme-linked immunosorbent assay (ELISA) 
Recently, the enzyme-linked immunosorbent assay (ELISA) has replaced the IFF 
technique. It is most commonly used in clinical laboratory to detect ANA. This assay is based on 
antigens extracted from HEp-2 cells, or on recombinant antigens (Buchner et al., 2014; Copple et 
al., 2011; Emlen & O'Neill, 1997). There are different ELISA kits for ANA detection, and they 
are differ in sensitivity and specificity. The specificity of ELISAs for ANA test depends on the 
quality of antigens used. Therefore, it is very important to use the antigen with same sequence 
and conformation of human antigen (Cabiedes & Nunez-Alvarez, 2010; Copple et al., 2011).  
Regarding ANA detection test in clinical laboratories, a screening of ANA test is firstly 
performed. Then, the positive ANA results are processed for Anti-ENA, or Anti-dsDNA ELISA 
kits in order to characterize the antinuclear antibodies presented in the patient sera. In screening 
ANA test, the ELISA wells are coated with a mixture of several nuclear antigens including: 
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dsDNA, histones, ribosomal P‐proteins, nRNP/Sm, Sm, SS‐A, SS‐B, Scl‐70, Jo‐1, centromeres. 
Anti-ENA ELISA is separately coated with specific antigens on the ELISA wells including: 
nRNP/Sm, Sm, SS‐A, SS‐B, Scl‐70, Jo‐1.  The other kit of anti-dsDNA, the wells are coated 
with dsDNA. Hence, ELISA is specific and sensitive technique for ANA screening, and also for 
ANA characterization (Abeles & Abeles, 2013; Agmon-Levin et al., 2014; Copple et al., 2011; 
Gill et al., 2003; Kumar et al., 2009; Mahler, Pierangeli, et al., 2014; Meroni & Schur, 2010; 
Neogi et al., 2010; Pisetsky, 2012).  
1.4.3. Western blot assay 
This assay is used to characterize the auto antibodies presented in the serum of patient. It 
is based on the nuclear proteins separation according to their molecular weight by sodium 
dodecyl sulphate- polyacrymide gel electrophoresis (SDS-PAGE). The separated proteins are 
transferred onto a nitrocellulose membrane. Then, it is cut into strips to test the sera after a 
period of incubation time. This way, the auto antibodies existed in the sera are bound to specific 
antigens on the membrane.  In order to detect the reaction between the antibodies and antigen 
after adding the second antibody, different methods can be done, most commonly are 
colorimetric and chemilumilenscence reaction. The positive results are shown as a band on the 
strip. Further, the band appeared on the strips are either compared to the marker or to the positive 
controls to identify the autoantibodies (Kumar et al., 2009).   
However, previous studies showed that this technique only detects linear epitopes but not 
the conformational ones. Therefore, it may not detect anti-SSA/Ro and anti-Scl70 (Kumar et al., 
2009). 
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The aim of study 
 
The main aim of this study is to develop an ELISA test for screening systemic 
autoimmune diseases (SARD) using continuous cell-line culture and high rich DNA cells. The 
specific objectives are: 
1- To identify and collect sera from different patients with systemic autoimmune 
diseases. 
2- To test THP1 cell lines for their suitability in diagnosis of systemic autoimmune 
diseases using ELISA test. 
3-To test the suitability of using Kinetoplast DNA rich non-pathogenic parasite 
(Leishmania tarentolae) for diagnosis of systemic autoimmune diseases using ELISA 
test. 
4- To correlate the different obtained ELISA results with the results of immune-blotting 
assay using different Leishmania tarentolae and THP1 cells antigenic extracts.  
 
5- To compare the obtained results of both used ELISA systems and immunoblotting 
with the results obtained using commercial kits for the detection of systemic autoimmune 
diseases.  
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Materials & Method 
2.1 Sample collection and transportation 
47 samples were collected from Al-Makassed hospital laboratory after obtaining approval 
from the hospital manager. The duration of sample collection was from July, 2013 until 
September, 2016.  
2.2 Data collection 
The data of patients who have positive ANA were collected from the archive department at 
Al-Makassed hospital. The data included age and gender. The patient age was included only for 
individual, who has a registration number at the hospital.   
 2.3 Tissue culture 
A ready cultured THP1 and Leishmania tarentolae cells were used. The cells were 
counted, and observed under an inverted microscope for next passage preparation. Then, sub 
cultured into several flasks using fresh DMEM and RPMI with 10% FCS, 1mg of L-Glutamine, 
10mg/ml of penciling-streptomycin (Sigma, USA). Media was filtered.  For Leishmania sub-
culturing, 1 ml from ready leishmanial culture media was added to 9ml from prepared RPMI 
media. Then, they were incubated at 26-28 °C. After 3 days, the growth of leishmania was seen 
under an inverted microscope to see if they need further sub-culturing. If the color was changed 
into yellow, the sub culturing was done immediately. For THP1 cells, the sub-culturing was done 
with dilution of 1:1 using DMEM media, then, incubated at 37 °C for 3 days, and monitored 
under inverted microscope to examine the cell’s growth. 
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2.4 Cell counting 
The counting of Leishmania tarentolae and THP1 cells was done manually on a 
hemocytometer slide using an optical microscope. The average cell count was calculated for all 
cells counted in each square, and multiplied by 10000.  
 2.5 Extraction of cytoplasmic and nuclear fractions 
Regarding nuclear extraction from nucleus of THP1, and cytoplasmic extraction from 
Leishmania tarentolae, the cultured media with total cell count of 10
5 
cell/ml were taken into a 
50ml sterile falcon tube, centrifuged at 2500 rpm for 10 mins. Pallet was washed using 10 ml 
1XPBS-T, and collected at 2500 rpm for 5 mins. 
 
Cytoplasmic and nuclear extraction was done by adding 400 μl from cytoplasmic buffer 
(10mM HEPES, 60 mM KCL, 1mM EDTA, 0.075% (v/v) NP40, 1mM DTT and 1mM PMSF, 
pH 7.6) to the tube in order to resuspend the pellet. Then, the suspension was incubated on ice 
for 3 min, centrifuged at 1500 rpm for 4 mins, and the supernatant (cytoplasmic extract) was 
transferred into a clean tube. Afterward, 400 μl from cytoplasmic buffer without detergent NP40 
was added to wash the pellet, centrifuged again at 1500 rpms for 4 min. After that, 200 ul from 
nuclear buffer (20 mM Tris NaCl, 1.5 mM MgCl2, 0.2mM EDTA, 1 mM PMSF, and 25% (v/v) 
glycerol, pH 8) was added, and  200 μl 5 M NaCl was also added to adjust the salt concentration. 
Then, another 200 μl from nuclear buffer was added. Finally, the extract was incubated on ice for 
10 mins, and then, it was mixed using the vortex.  The final extracted nuclear, and cytoplasmic 
fractions were frozen at – 20 °C.  
2.6 Salmon sperm DNA preparation 
 The concentration of salmon sperm DNA solution was prepared to be 0.1% (w/v) in 
double distilled water. 
18 
 
2.7 Protein and DNA quantitation 
The DNA and protein concentration of THP1 nuclear fractions and leishmanial 
cytoplasmic extracts were measured by spectrophotometer. The optical density was read at 260 
nm for DNA quantitation, and at 280 nm for protein quantitation. The concentration of DNA and 
protein were determined using the following equations:  
 For protein: 1 OD at 280nm= 1mg/ml 
 For DNA: OD at 260nm * 0.05 ug/ul * DNA dilution 
2.8 Enzyme Linked Immunosorbent Assay (ELISA) 
Each extract from salmon sperm DNA, Leishmania tarentolae and THP1, were coated in 
different concentration: 10, 50 and 100 ng/ml, into separate polystyrene flat bottom 96 wells 
ELISA plates. Then, 100 μl from each were coated into separate plates. Kept at 4˚C for 3 days, 
washed three times with 1XPBS with 0.05 Tween-20 solution very well to remove the excess of 
uncoated antigens. 100 μl from blocking solution (5% FCS-PBS-T) was added for half an hour. 
Then, first antibody was added, a total of 47 samples and negative control sera. All were tested 
using extracts from the cells mentioned above. The dilution of sample was 1:100 and 1:200. All 
samples were tested in duplicates. After two hours of incubation at room temperature, the 
contents were discarded and wells were washed three time with 1XPBS. 100 μl diluted protein 
A-HRP (1:6000) was added as second Abs and incubated for 1 hour at room temperature, 
washed three times with PBS-T. 200 μl of the substrate-chromogen solution (1mg of the O-
phenyldiamine to each 1ml pf citrate buffer (PH 4.5) then 4 μl of the substrate H2O2 was added 
to each 10 ml of the citrate buffer containing the chromogen and incubated for 30 minutes at 
room temperature, color development was measured at 490 nm by using ELISA reader. 
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2.9 Immunoblotting (Western blot) 
 The immunoblotting technique was performed according to Towbin et al (Towbin, 
Staehelin. & Gordon 1979) in order to characterize the autoantibodies found in positive ANA 
sera. A total number of 23 positive sera were tested against Leishmania tarentolae cytoplasmic 
extract, and 28 positive sera were tested against THP1 nuclear extracts. In addition, 5 negative 
sera were tested in each trial.  
2.9.1. SDS-PAGE Gel preparation 
 Mini-PROTEAN casting stand and frame (BIO-RAD) were assembled. In order to make 
10% resolving gel, 4.7ml of double distilled water were added to a clean tube. Then, 2.5 of 40% 
polyacrylamide, 2.6 of 1.5M Tris-HCl, pH 8.8 and 100 μl from 10% SDS were also added. 100 
μl from Ammonium persulfate (APS) and 10 μl from Tetramethylethylenediamine (TEMED) 
were the last material added, then all were mixed and poured in the glass plates. The gel were left 
for about 20-30 min at room temperature to make sure gel had polymerized. Then, 5% stacking 
gel was prepared by adding 6.2 ml from double distilled water, 1ml of 30% polyacrylamide, 2.6 
ml of 0.5 M Tris-HCL pH 6.8, 100 μl from 10% SDS, 100 μl from 10% APS and 10 μl from 
TEMED. They were mixed and poured on top of resolving gel. The gel was poured until it 
reached to the end of glass plate, then, comb were inserted, and left for another 20-30 mins. 
  
2.9.2. Sample preparation and loading 
 Before loading the extracts into the wells of polyacrylamide gel, two volume of extracts 
were mixed with one volume of loading buffer (Bromophenol 0.004%, 2-mercaptoethanol 10%, 
Glycerol 20%, SDS 4%, Tris-HCl 0.125). Then, the mixture was heated in a water bath at 95 C 
for 10 min. 
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2.9.3. SDS-PAGE Gel Electrophoresis 
 The gels were soaked in 1X running buffer (SDS 0.1%, Tris-HCl 25mM and glycine 
200mM) inside the gel electrophoresis tank. After that, 5 μl from the molecular size marker 
(New England Biolabs Inc, Beverly, MA, USA) was loaded into one well of each 
polyacrylamide gel, and 20 μl from the mixture was loaded into each of 7 wells. The 
electrophoresis was carried out at 50 V for about 1 hour, then the voltage was increased at 100 V 
for another 2 hours.  
 
2.9.4. Western blotting- Gel transfer 
 After separation the proteins using SDS-PAGE gel, they were transferred into 
nitrocellulose filter membrane (Schleicher and Schauell, Dassel, Germany). The polyacrylamide 
gel was soaked into 1X transfer buffer (0.025 M Tris-HCl, 0.192 M Glycine, and 20% 
methanol).   Then, the gel and the nitrocellulose filter membrane were firmly gathered together 
inside the gel holder cassette. The gel holder cassette was inserted into Mini Trans-Blot tank 
filled with 1X transfer buffer (0.025 M Tris-HCl, 0.192 M Glycine, and 20% methanol), then the 
transfer was carried out at 100 V for one hour. Then, the membrane was stained by Ponceau S 
(0.1% w/v in 1% v/v acetic acid) (Sigma, Sant Louis, USA) for 1 minute followed by destaining 
in 1XPBS. 
 
2.9.5. Blocking, first antibody and secondary antibody incubation  
 Each membrane was cut into strips. These strips were blocked by 1X PBST plus 5%FCS 
for one hour. The following step, 2ml of 1:200 diluted sera with 1X PBST plus 5% FCS were 
added to the strips. Then, incubated for 2 hours at room temperature. The strips were washed 3 
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times using 1X PBST. Secondary antibody (1:4,000 dilution, Protein A) was added to each strip, 
and incubated for 1 hour. After incubation, strips were washed three times using 1XPBST.  
 
2.9.6. Electrogenerated Chemiluminescence ECL 
 ECL detection was performed immediately after streptavidin-HRP incubation and 
washing using EX-ECL detection kit (Biological Industries, Beit Haemek, Israel). 
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Results 
 
 
3.1 Pilot study for the previous positive ANA cases:  
Records (2012-2015) of Al-Makassed hospital, showed that 2,102 from in and out-patient 
had done ANA test.  Only total of 147 individuals were found to be ANA positive (Table 3.1). 
From the 147 positive cases; 121 cases were females and it was clearly seen that number of cases 
in females are always more all over the pilot study survey.   
Table 3.1: Total number of ANA diagnosed individuals at Al-Makassad hospital laboratory 
during (2012-2015).     
Year Number of tested samples Number of positive cases according to gender 
 Male Female Total Male Female Total 
2012 204 313 517 6 41 47 
2013 204 293 497 6 26 32 
2014 247 321 568  8 34 42 
2015 200 320 520 6 20 26 
Total 855 1,247 2,102 26 121 147 
 
 
 
Table 3.2 represents the number of positive cases according to age (only from in-patient 
hospital clinic); in which it can be seen that most of the diagnosed cases were between (22-30), 
(31-40), and (41-60) years, while less cases were discovered in early ages or later in life.  
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   Table 3.2: Total number of ANA diagnosed individuals at Al-Makassad hospital 
   laboratory grouped according to age (2012-2015). 
Year Number of positive samples according to age  
 0-5 6-12 13-21 22-30 31-40 41-60 60-80 >80 
2012 3 0 0 6 3 10 2 0 
2013 5 4 2 8 2 5 5 1 
2014 0 0 1 9 6 9 0 0 
2015 0 0 5 4 7 8 2 0 
Total 8 4 8 27 18 32 9 1 
 
 
 
3.2 Optimization of Enzyme linked immunoassay (ELISA): 
3.2.1. ELISA based on whole intact cells: 
 Three different types of cells (THP1, 3T3, and Leishmania tarentolae cells) were used in 
pilot study that aimed to find the most suitable antigen to be used in ANA-ELISA system. At the 
begging all these cells were used as intact cells and in a concentration of 10
5
/ml in DMEM media 
for both THP1 and 3T3, while for Leishmania tarentolae cells were diluted in RPMI media. 
Different ELISA plates were coated with 100 μl of each of the three cell type, plates were kept 
overnight at 4
o
C. The coated plates were tested with 1:100 and 1:200 diluted sera from 
previously collected ANA positive samples and with known negative control sera. For the three 
types of cells only sera samples with high ANA antibody titer gave significant optical density 
readings compared to negative controls with no superior results concerning the type of the used 
cells. Figure 2 shows ELISA plate coated with Leishmania tarentolae cells and its reactivity 
against the tested sera. Similar results were obtained for the other cells.  
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3.2.1. ELISA results using different sources of DNA. 
 In order to optimize ELISA conditions to follow up the reactivity of ANA positive sera 
against dsDNA; two different types of DNA were used: 1- DNA that was extracted from cattle 
liver tissue and 2- Salmon sperm DNA (ssDNA), that was commercially purchased (Sigma, St. 
Louis, USA). Initially; the two different types of DNA were used in coating ELISA plates in 4 
different concentrations (10ng/ml, 50ng/ml, and 100ng/ml). Also two different types and 
concentrations of second antibodies (anti-human IgG and protein-A) were tested. Coating plates 
with 100ng/ml of ssDNA combined with protein-A gave the optimal results for performing ANA 
 
 
 
 
 
Figure 3.1: ELISA plate coated with Leishmania tarentolae cells that was used to test 1:100 
and 1:200 diluted ANA negative sera (negative samples 2,3,4,5 ( A-D), and other ANA 
positive sera samples (6-12/A-D), and (1-12/E-H). Blank (1/A-D) 
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ELISA taking into consideration the maximum number of reactivity with different ANA selected 
positive samples and no reactivity with negative control sera. 
 
3.3 Enzyme linked immunoassay of ANA positive sera against antigenic preparations.  
 A total number of 47 positive sera samples were obtained from Al-Makassed hospital. 
The ANA positivity of the obtained samples was confirmed using ANA-screening test 
(Euroimmun ANA screening kit, Leubeck, Germany). The characterization of auto-antibodies in 
these individuals was performed using (Euromen ENA profile and Euroimmun anti-dsDNA, 
Leubeck, Germany) and it was conducted in Al-Makassed laboratories for some samples and the 
rest of the samples were characterized in Al-Quds University. For the obtained 46 samples; 29 
samples were tested against salmon sperm DNA (DNAss), 47 samples were tested against 
cytoplasm extract from Leishmania tarentolae cells, and nuclear extract from THP1 cells.   
Figure 3.2 shows the ELISA results of the tested positive sera in two different dilutions 
(1:100 and 1:200). The obtained ELISA results using DNAss extract as antigen showed 100% 
positivity in 1:100 antibody titer and 65% positivity using 1:200 antibody titer. Similarly; the 
ELISA results were found to be positive in all tested samples against Leishmania tarentolae 
cytoplasmic extract and THP1 cells nuclear extracts at 1:100 antibody dilution. While at 1:200 
antibody dilution the results were positive for 85% of samples using Leishmania tarentolae 
cytoplasmic extract, and 91% using THP1 cells nuclear extracts. 
Table 3.3, show the calculated average results (optical density readings) for 29 serum 
samples tested against salmon sperm DNA and for 47 sera samples tested separately against 
Leishmania tarentolae cytoplasmic extract and THP1 nuclear extract. Any reading below the 
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cut-off value was indicated as a negative result. The cut-off value was calculated using the 
results of negative samples that were run in same ELISA of the indicated antigens.  
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Figure 3.2:  The percentages of positive ELISA results of the tested 
samples using two different antibody titers and against three different 
antigenic preparations.  
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Sample 
# 
Salmon sperm 
DNA 
Leishmania 
cytoplasmic extract 
THP1  
nuclear extract 
ANA 
profile 
   1:100 1:200 1:100 1:200 1:100 1:200  
Sampe1’ Negative Negative Negative Negative Negative Negative ND 
Sample2’ Negative Negative Negative Negative Negative Negative ND 
Sample3’ Negative Negative Negative Negative Negative Negative ND 
Sample4’ Negative Negative Negative Negative Negative Negative ND 
Sample5’ Negative Negative Negative Negative Negative Negative ND 
Sample6’ Negative Negative Negative Negative Negative Negative ND 
Sample7’ Negative Negative Negative Negative Negative Negative ND 
1 0.203 Negative 0.5 0.346 0.7645 0.4955 Anti- 
SSA+SSB 
2 ND ND 0.5 0.3385 0.8765 0.4425 Anti- SSA 
3 0.66 0.306 0.399 0.173 0.329 0.1855 Anti- 
SSA+SSB 
4 0.405 0.255 0.4605 0.259 0.4215 0.1965 ND 
5 0.692 0.4635 ND ND ND ND Anti- 
dsDNA 
6 0.7545 0.2315 0.4 0.198 0.3875 0.1375 Anti- 
SSA+SSB 
7 0.6465 0.2695 0.7355 0.3645 0.775 0.648 Anti- 
SSA+SSB, 
nRNP 
8 0.394 0.159 0.4845 0.199 0.334 0.1795 ENA -ve 
9 0.4925 0.1895 0.463 0.1605 0.2365 0.154 Anti- 
dsDNA 
10 0.553 0.2695 0.632 0.314 ND ND ENA -ve 
11 0.345 0.2415 0.353 0.1975 0.4185 0.219 Anti-nRNP-
sm 
12 0.204 Negative 0.595 0.2515 0.73 0.5475 Anti-dsDNA 
13 ND ND 0.4305 0.188 0.342 0.218 ND 
14 2.5 2.126 1.6755 1.152 1.5 1.0 Anti- 
dsDNA 
15 0.8025 0.2505 0.4585 0.2095 0.527 0.275 Anti-dsDNA 
+ sm 
16 0.2625 0.1755 0.3955 0.2895 0.777 0.7135 Anti-nRNP-
sm 
17 0.2535 0.177 0.682 0.3355 0.787 0.5023 Anti-
SSA+SSB 
18 0.412 0.259 0.2245 Negative 0.3345 0.173 Anti-
SSA+SSB 
19 1.6545 0.5815 0.3255 0.162 0.9465 0.39 Anti-dsDNA 
20 0.2465 Negative 0.484 0.3375 0.5825 0.446 Anti-
SSA+SSB 
Table 3.3: The results of tested ANA positive samples using ELISA against salmon 
sperm DNA, Leishmania tarentolae cytoplasmic extract and THP1 nuclear extract. The 
results are expressed as spectrophotometric absorbance values 
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21 0.2195 Negative 0.53 0.211 0.418 0.2185 ENA -ve 
22 1.9 0.951 0.39 0.197 0.6075 0.342 Anti-nRNP-
sm +SSA 
23 0.2 Negative 0.567 0.2325 1.2795 0.389 ENA -ve 
24 0.3515 Negative 0.574 0.395 0.5795 0.4255 Anti- Scl-70 
25 0.234 Negative 0.3295 0.2605 0.4545 0.34 ENA -ve 
26 0.3535 Negative 0.9015 0.2325 1.215 0.5425 Anti- nRNP-
sm 
27 0.228 Negative 0.27 0.1915 0.2525 0.189 Anti-SSA 
28 1.1535 0.26 0.5 0.2755 1.5 0.6755 ENA -ve 
29 1.08 0.2445 0.2885 0.1445 0.427 0.2145 Anti-nRNP-
sm 
30 1.0275 0.27 0.3 0.151 1.1155 0.555 ND 
31 0.151 Negative 0.1875 0.155 0.3985 0.3105 ND 
32 ND ND 0.3 0.175 0.479 0.279 Anti-nRNP-
sm 
33 ND ND 0.2515 Negative 0.254 Negative ND 
34 ND ND 0.776 0.247 1.777 1.347 ND 
35 ND ND 0.3195 Negative 0.2485 Negative Anti-SSA 
36 ND ND 0.368 0.205 0.589 0.2975 Anti-
nRNP/sm 
37 ND ND 0.458 0.1765 0.28 0.1965 ND 
38 ND ND 1.208 1.0085 1.641 1.1315 Anti-
nRNP/sm 
39 ND ND 0.5475 0.2995 0.667 0.361 Anti-SSA 
40 ND ND 0.289 Negative 0.244 Negative ND 
41 ND ND 0.2945 Negative 0.7175 0.262 Anti-dsDNA 
42 ND ND 0.282 Negative 0.2465 0.2025 Anti-
SSA+SSB 
43 ND ND 0.3465 Negative 0.6425 0.206 ND 
44 ND ND 0.275 0.176 0.2695 Negative ND 
45 ND 
 
ND 0.276 Negative 0.244 Negative Anti-
nRNP/Sm 
&SSA 
46 ND ND 0.395 0.284 0.3255 0.204 Anti-SSA 
47 ND ND 0.9695 0.834 1.554 1.133 Anti-
SSA+SSB 
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The ELISA results of tested ANA positive serum samples were presented in a separate 
dot blot figure for each antigen in the ELISA test (Figure 3.3). Higher optical density readings 
were obtained upon the use of salmon sperm DNA as an antigen compared to other cell extracts 
at dilution 1:100, and although the readings were still higher in 1:200 dilutions; some samples 
turned to be negative compared to the same samples that were shown to be positive against the 
other used Leishmania tarentolae cytoplasmic extract and THP1 nuclear extract. The optical 
density reading of the THP1 nuclear extract were relatively higher than those obtained using 
Leishmania tarentolae cytoplasmic extract, with more positivity upon the use of 1:200 diluted 
sera samples, a results that reflected more specificity of this antigen in ELISA format approach 
for the detection of ANA/ENA antibodies. A full discussion of this finding and its future benefits 
is highlighted in the discussion. 
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Leishmania tarentolae
cytoplasmic extract 
1:100 1:200
THP1 
nuclear extract
Figure 3.3: The result of tested ANA positive samples in ELISA against 
salmon sperm DNA, Leishmania tarentolae cytoplasmic extract and 
THP1 nuclear extract. 
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3.4 Western-Blot analysis of ANA positive sera samples against Leishmania tarentolae 
cytoplasmic extract and THP1 cells nuclear extracts. 
 The immune-blotting profile of the reactive auto-antibodies found in ANA positive serum 
were analyzed using Western-Blot method. A total of 23 samples were analyzed against proteins 
of Leishmania tarentolae cytoplasmic extract, and another 29 ANA positive sera samples were 
analyzed against nuclear extract from THP1 cells. From these samples; 19 different positive sera 
were shared in this analysis using the tow extracts, and external negative control sera were also 
included. All tested samples were diluted 1:100 in antibody dilution buffer (PBST-FCS) before 
anlaysis.   
Figure 3.4 shows the reactivity profile of autoantibodies in the tested ANA positive sera 
against Leishmania tarentolae cytoplasmic proteins. A band with molecular size of 48 kD 
appeared in some strips, specifically strips number (7, 8, 9, 10, 18, 19, 23, 24 and 25). Strips 
number: 5, 6, 7 and 19 showed reactivity to a 60 kD band. While strips number 15, 17, 21 and 
22, were reactive with a band of 18 kD. Other smaller band size in a range of 9-30 kD were also 
detected in other strips.  The importance of these findings and their correlation to the clinical 
finding in each of the tested ANA positive sera is shown below. 
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Figure 3.4: Immuno-blotting reactivity of ANA posittve sera against SDS-
PAGE separated molecules from Leishmania tarentolae cytoplasmic 
extract.  
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The immune-blotting pattern of the tested ANA positive sera against THP1 nuclear 
extract proteins is shown in figure 3.5.  Most of the strips showed reactivity with different bands 
in a range of 25 to 70 kDa, although some strips showed no reactive bands (strip number 
11,12,19,20 and 21). In details: a band with molecular size of 30 kDa appeared in strip 9, 13 and 
16.  While 48 kDa band showed in strips numbered: (5c, 11c, 6, 7, 8, 14, 15).  50 kDa band 
appeared in 4c, 17 and 18, and 60kDa band appeared in 8c, 6, 10 and 17.  The strip of 5c and 7c 
show 25kDa band. 35 kDa band was appeared in strip # 9c. A band with molecular size of 70 
kDa appeared on strips 6c and 10c.  
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Figure 3.5: Immuno-blotting reactivity of ANA posittve sera 
against SDS-PAGE separated molecules from THP1nuclear 
extract.  
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3.5 Similarity between ENA profiles and immuno-blotting results of the tested ANA 
positive sera:  
 The ENA profile test for the selected ANA positive sera samples was determined using 
commercial kit (Euroimmun, Leubeck, Germany), the main purpose of this test was to determine 
the type of autoantibodies in patients sera. The tested antigens in this kit were extracted from calf 
thymus, and include 6 different antigens: nRNP/sm, sm, SS-A, SSB, Scl-70 and Jo-1.  The 
molecular weight of nRNPs and sm are ranging from 9 to 29.5 kDa. While SS-A, SSB, Scl-70 
and Jo-1 have molecular weights of 60, 48, 70 and 50 kDa respectively.  
 Table 3.4 shows the combined results of 23 positive ANA sera in terms of ENA profile, 
anti-dsDNA test, results of leishmanial ELISA extract, and together with the obtained 
immunoblotting banding pattern. As shown, Most of these tested positive sera and in a dilution 
of 1:100 were positive in ELISA testing against leishmanial extracts and all were reactive upon 
immunoblotting analysis. However, not all of these bands were related to ENA profile.  
 Sample # 6, strip# 6 gave a band with molecular size of 60 kDa which is similar to SSA 
antigen molecular weight. As shown in table 3.4, sample 6 has a profile of anti-SSA and anti-
SSB autoantibodies. In addition, the 60 kDa band with another band sized 48 kDa were seen in 
strip # 7, sample #7.  The 48 kDa band is predicted to be SSB antigen, as the sample #7 also 
showed anti-SSA and anti-SSB. Similarly, samples number 18, strip number 18, also showed 48 
kDa band. Other samples, such as # 15, 18 and 22 they showed a band size close to 18 and 20 
kDa, and their profile was found  to be  anti-sm or anti-nRNP/sm autoantibodies, so, it is 
expected that these bands were related to nRNP and sm antigens.  
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strip # Sample # Band MW 
(kDa) 
ENA profile and dsDNA 
test 
Leishmanial extract 
ELISA result 
1 - -ve ND -ve 
2 - -ve ND -ve 
3 - -ve ND -ve 
4 4 30, 18 ND +ve 
5 5 30, 60 Anti-dsDNA +ve 
6 6 9. 60 Anti-SSA&SSB +ve 
7 7 48, 60 Anti-SSA&SSB 
Anti-nRNP/sm 
+ve 
8 8 48 ENA -ve +ve 
9 9 9, 49 Anti-dsDNA +ve 
10 10 15, 48 ENA -ve +ve 
11 11         30 Anti-nRNP/sm +ve 
12 12 27, 100 Anti-dsDNA +ve 
13 13 27,35, 70 ND +ve 
14 14 38,27 Anti-dsDNA +ve 
15 15 18 Anti-dsDNA 
Anti-sm 
+ve 
16 16 20, 80 Anti-nRNP/sm +ve 
17 17 18, 30 Anti-SSA&SSB +ve 
18 18 48 Anti-SSA&SSB +ve 
19 19 48 
60 
Ant-dsDNA +ve 
20 21 48 ENA –ve +ve 
21 22 18, 100 Ant-nRNP/sm 
Anti-SSA 
+ve 
22 23 35, 18 ENA –ve +ve 
23 24 35, 48 Anti-Scl70 +ve 
24 25 48 ENA –ve +ve 
25 26 48 Anti-nRNP/sm +ve 
26 36 15 Anti-nRNP/sm +ve 
Table 3.4: Summary of the immuno-blotting results of the ANA positive sera reacted 
against Leishmania tarentolae cytoplasmic extract and their correlation to the found 
ENA profile results. 
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Similarly, the result of 24 positive ANA sera samples, summarized in table 3.5 taking 
into account the ENA profile and the obtained immunoblotting results against THP1 nuclear 
extract in correlation to ELISA results. However, 5 samples did not show any reactive bands. 
Samples (Sample #/strip#) 1/6, 2/7, 3/8, 7/5c, 17/14 and18/15 showed a band with size 48 kDa, 
and these samples at least were positive for anti-SSB. Sample #1 strip# 6 also showed a 60kDa 
band, as well as  samples (sample/strip): 6/10 and 20/17. The 60 kD band is expected to be for 
SSA antigen, as these samples showed a positive result for this antigen. However, sample/strip 
6/10 and 20/17 showed another band sized 50 kDa, that indicated the presence of SSB antigen. 
Other samples that show positive reaction in ENA profile for nRNPs/sm or for sm antigens, 
showed a band ranging from 25 to 35 kD, such as (sample #/strip#):  15/13, 7/5c, 16/9c.  The 
sample # 24/ strip# 10c showed a band with size 70 kDa. Based on ENA profile results, this 
sample was positive for anti-Scl70. Thus, this band was predicted to be antigen Scl70.  
 
 
 
 
 
 
 
38 
 
 
 
strip # Sample # Band MW 
(kDa) 
ENA profile and 
dsDNA test 
THP1 extract 
ELISA (1:100) 
1 - -ve ND -ve 
2 - -ve ND -ve 
3 - -ve ND -ve 
4 - -ve ND -ve 
5 - -ve ND -ve 
6 1 6,18, 48,60 Anti-SSA&SSB +ve 
7 2 48 Anti-SSB +ve 
8 3 48 Anti-SSA&SSB +ve 
9 5 30 Anti-dsDNA +ve 
10 6 60 Anti-SSA&SSB +ve 
11 12 -ve Anti-dsDNA +ve 
12 14 -ve Anti-dsDNA +ve 
13 15 30 Anti-dsDNA 
Anti-sm 
+ve 
14 17 48 Anti-SSA&SSB +ve 
15 18 48 Anti-SSA&SSB +ve 
16 19 30 Anti-dsDNA +ve 
17 20 52, 60 Anti-SSA&SSB +ve 
18 22 50 Anti-snRNP/sm 
Anti-SSA 
+ve 
19 23 -ve ENA –ve +ve 
20 26 -ve Anti-nRNP/sm +ve 
21 28 -ve ND +ve 
22-4c 4 50 ND +ve 
23-5c 7 25, 48 Anti-SSA&SSB 
Anti-nRNP/sm 
+ve 
24-6c 8 70 ENA -ve +ve 
25-7c 9 25 Anti-dsDNA +ve 
26-8c 10 60 ENA -ve +ve 
Table 3.5: Summary of the immuno-blotting results of the ANA positive sera 
reacted against THP1 nuclear extract and their correlation to the found ENA 
profile results. 
 
39 
 
27-9c 16 35 Anti nRNP/sm +ve 
28-10c 24 70 Anti-Scl-70 +ve 
29-11c 25 48 ENA -ve +ve 
 
A comparison between the immunoblotting banding pattern obtained by the use of 
leishmanial cytoplasmic and THP1 nuclear extracts is summarized in table 3.6, in which the 
results of 19 shared sera samples were analyzed by all tests. As it can be seen from this table, 
only 6 samples gave a shared banding pattern upon the use of leishmanial and THP1 extracts in 
immunoblotting analysis. From these samples, only the result of 3 samples were related to ENA 
profile; for example, sample number 6 showed a band sized 60 kDa in both leishmanial and 
THP1 extract strips, and they also showed a positive reaction for SSA antigen. While in sample 7 
and 18, they gave a positive result for a band size of 48 kDa in both extracts, leishmanial and 
THP1, which was the same molecular weight for SSB antigen.  
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Number Sample # Bands in strip of 
Leishmania tarentolae 
(MW in kDa) 
 Bands in strip of 
THP1 
(MW in kDa) 
Autoantibodies 
profile 
1 5 30, 60 30 Anti-dsDNA 
2 9 9, 49 25 Anti-dsDNA 
3 12 27, 100 -ve Anti-dsDNA 
4 14 38,27 -ve Anti-dsDNA 
5 19 48, 60 30 Anti-dsDNA 
6 15 18 30 Anti-dsDNA 
Anti-sm 
7 6 9, 60 60 Anti-SSA&SSB 
8 17 18, 30 48 Anti-SSA&SSB 
9 18 48 48 Ant-SSA 
&SSB 
10 7 48, 60 25, 48 Anti-SSA&SSB 
Anti-nRNP/sm 
11 22 18, 100 50 Anti-snRNP/sm 
Anti-SSA 
12 26 48 -ve Anti-nRNP/sm 
13 16 20, 80 35 Anti nRNP/sm 
14 24 35,48 70 Anti-Scl70 
15 8 48 70 ENA -ve 
16 23 35,18 -ve ENA –ve 
17 10 15, 48 60 ENA -ve 
18 25 48 48 ENA –ve 
19 4 30, 18 50 ND 
 
 
Table 3.6: The correlation results between Leishmania tarentolae and THP1 
immunoblotting and ENA profile testing 
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Discussion 
 
The anti-nuclear autoantibodies are self-reactive antibodies that attack different self-
nuclear antigens. They are known to be presented in patients with autoimmune disorders as result 
of peripheral immune tolerance breakdown. This may be due to different triggered caused by 
genetic or any other factors such as environment and hormones. Patients with Systemic 
Autoimmune Rheumatic Disease (SARD) are suspected to have more than one anti-nuclear 
autoantibodies targeting different organs in the body, leading to severe injuries in tissues and 
organs. Women are known to be more susceptible to develop Systemic Autoimmune Rheumatic 
Disease (SARD). For example, it was reported that Systemic Lupus Erythematosus (SLE) affects 
women ten times more than men (Danchenko et al., 2006). In other autoimmune disease, a 
different study reported that 9 women to 1 man are affected with sjogren syndrome 
(Manoissakls, 2001). In this pilot archive data regarding diagnosed patients with positive ANA at 
Al-Makassed laboratory hospital during the years (2012-2015), it was found that women were 
more affected than men in terms of autoimmune disorder. Different studies explained the 
possible reasons for sex difference in autoimmune disorder development. For example, the 
immune system of women produce more antibodies and T helper 2 cells against external foreign 
antigens. Thus, the high level of antibodies increases the risk of developing an autoimmune 
disease. Furthermore, estrogen is known to be capable of altering the immune response and 
developing autoimmune disease (Beeson, 1994; Cutolo et al., 2012). 
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  Autoimmune disease can be developed at any age (Manuel J., Alberto & Gladis 2012). 
However, the age onset of autoimmune disease depend on the type of the disease. For example, 
In SLE disease, 56% of patients start to show symptoms between ages 16 and 55, while 35% of 
them show symptoms before age 16, and after age 55. However, In Sjögren’s syndrome, patients 
between ages 45 and 50 are more susceptible to have the disease. Another autoimmune disease 
can develop between ages 30 and 50, such as rheumatoid arthritis.  In this study for positive 
ANA cases during (2012-2015), table 3.2. It was also found that autoimmune disease strikes all 
ages. However, most of the diagnosed cases were between (22-30), (31-40), and (41-60) years, 
while less cases were discovered in early ages or later in life.  
For the antinuclear autoantibodies detection and identification, the Indirect Immuno-
fluorsent technique (IIF), and Enzyme Linked Immunosorbent assay (ELISA) which are still in 
use for that purpose. In addition, Western blot technique is also performed to identify ANA in 
patient sera. In these techniques, different antigens were used from cells of liver, kidney, or 
thymus that are taken from either mice or calves. Scientists tend to target these organs because 
their cells have many large nucleus. Recently, the most cells used in IFF and ELISA are HEp-2 
cells, which are originated from human laryngeal squamous cell carcinoma. They show a high 
rate of division in culture, also their cells have large nuclei. In addition, hundreds of antigens 
existed on their surfaces. So that, they increase the sensitivity and specificity of the ANA test in 
both IIF and ELISA.  
In this study, 47 positive ANA sera samples were collected from Al-Makassed hospital 
laboratory. The sera samples were tested using the commercial kit of ANA screening, and ENA 
profile (Euroimmun, Leubeck, Germany). The ANA screening test helps only to determine if the 
sera sample contained anti-nuclear autoantibodies or not. If the result was positive, the sample 
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must be followed by another test, known as anti-ENA profile test. The main aim of this test is to 
identify the type of the anti-nuclear autoantibodies in the patient’s serum. These kits use purified 
antigens from calf thymus. The purified antigen of dsDNA, histones, nRNP/S, Sm, SSA, SSB, 
Scl-70, Jo-1, ribosomal-P proteins, and centromeres are prepared as a mixture to be coated in the 
ANA screening ELISA test. However, in anti-ENA profile test, only 6 antigens are coated 
separately. The 6 antigens are nRNP/Sm, Sm, SS-A, SS-B, Scl-70, and Jo-1. Furthermore, an 
additional test is required when the result of anti-ENA profile is negative which is known as anti-
dsDNA test. Hence, as these antigens are the most common antigens are targeted by the anti-
nuclear autoantibodies in SARD disease, most of clinical laboratories use the above mentioned 
kits and follow the steps of ANA testing, in order to give a proper diagnosis for the profile of 
anti-nuclear autoantibodies.  
Going deeply to discuss more about the main aim of this research, and discussing more 
about the result of ELISA tests: The antigenic preparation from salmon sperm DNA, THP1 cell 
and Leishmania tarentolae were used in ELISA, in order to develop an ELISA ANA screening 
test. Because the THP1 cells are human leukemia monocyte cell lines having unipolar nuclei, and 
the Leishmania tarentolae are non-pathogenic cells that are known to have a kinetoplast in the 
cytoplasmic region; which contains a network of circular DNA molecules, it was assumed that 
these cells will be suitable in ELISA for ANA screening. The results of ELISA assays using 
different antigenic preparations from the above indicated cells revealed that the use of salmon 
sperm DNA in ELISA assay gave higher OD readings compared to result of THP1 and 
leishmanial extract ELISA assays. It was clear from table 3.3 which represents ELISA reading 
results that these values were for sera samples with anti-dsDNA autoantibodies profile. 
Furthermore, the result of THP1 and leishmanial ELISA test, revealed that THP1 nuclear extract 
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was better than leishmanial extract for ANA screening test. Taken together, it is concluded that 
salmon sperm DNA is more suitable for anti-dsDNA ELISA assay. In addition, The THP1 
nuclear extract is more appropriate for ANA screening test than leishmanial extract. It is also 
concluded that the correspondence between the anti-nuclear autoantibodies and the 
conformational structure of THP1 nuclear antigens are greater than leishmanial extract, and this 
maybe because THP1 cells were taken from human. 
Furthermore, immunoblotting technique to characterize the anti-nuclear autoantibodies 
using the leishmanial cytoplasmic extract and THP1 nuclear extract was applied. The 
immunobotting results gave different bands on strips of both leishmanial and THP1. Some of the 
obtained bands were related to the anti-ENA profile, regarding the expected different antigens 
molecular weights. However, the results of THP1 were more related to anti-nuclear 
autoantibodies profile than leishmanial extracts. As most of anti-ENA profiles were anti-SSA 
and anti-SSB, most bands appeared were in a size of 48 kDa or 60 kDa. On the other hand, 
samples with both anti-SSA and anti-SSB profile, they mostly showed only one reactive band, 
either correlated with anti-SSA or with anti-SSB. Moreover, different bands appeared with size 
of 9-30 kDa. These bands may relate to nRNPs and sm proteins, or to centromere, histones and 
ribosomal proteins P. 
In conclusion, salmon sperm DNA, Leishmania tarentolae and THP1 protein extracts can 
be used as a screening antinuclear antibodies test depending on the results of ELISA and 
immunoblotting. However, more confirmed positive ANA using these different antigenic 
extracts must be tested for further confirmation, and to find a good correlation between the 
immunoblotting and ENA test. Furthermore, the immunoflourecent assay must be used to 
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identify the location in the THP1 and Leishmania tarentolae for antinuclear antibodies binding 
sites.   
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  .الانوية باستخدم خلايا مزروعة وخلايا الليشمانيا المتواجدة في روتيناتبال ل المختلفة  الكشف عن المضادات
  محمد بكرمي ابراهيم : اعداد
  الدكتور ابراهيم عباسي و الدكتور رسمي ابو الحلو: اشراف
 الملخص                                                                     
مستوى غير طبيعي عند المرضى الذين يعانون من بالأجسام المضادة للبروتينات وللمادة الوراثية داخل النواة تكون متواجدة 
يمكن الكشف عن هذه الاجسام المضادة باستخدام المصل من المريض لعمل فحص يدعى . ض الروماتيزم المناعة الذاتيةأمرا
 ecnecseroulfonummI tceridnIالاكثر شيوعا هي  ،هناك عدة تقنيات للكشف عن تلك الاجسام المضادة  .)ANA(ب 
لها القدرة  tolb nretsewوكذلك هنالك تقنية اخرى تدعى ب  yassA tnebrosonummI dekniL emyznEو  yassA
وكذلك  1PHT ىلقد استخدمنا في هذه الدراسة مستخلصات من انويه خلايا تدع. على الكشف عن تلك الاجسام المضادة 
ان تلك ف. mreps nomlaSبالاضافة الى المادة الوراثية من . استخدمنا مستخلصات السيتوبلازم من خلايا الليشمانيا
ظهرت النتائج ان تلك ألقد .yassA tnebrosonummI dekniL emyznE المستخلصات تم استخدامها في تقنية 
 ءكانت افضل شي mreps nomlaSولكن المادة الوراثية من . المستخلصات جيدة للكشف عن الاجسام المضادة للانوية
افضل من الليشمانيا للكشف عن الاجسام  1PHTخلايا  كانت مستخلصاتو ضادة للمادة الوراثيةمعن الاجسام ال للكشف
ولكن هذه النتائج  الحزم البروتينيةظهرت العديد من أفان نتائجها  tolb nretsewبالنسبة لتقنية . ة المختلفة الاخرىدالمضا
 .ا الليشمانياهي كانت ايضا افضل في هذه التقنية من خلاي 1PHTفان خلايا . ليست مرتبطة في نتائج الاجسام المضادة
 
 
